Concepedia

Publication | Open Access

A phase I study of indoximod in patients with advanced malignancies

DOIFull Paper Access

141

Citations

27

References

2016

Year

Hatem Soliman, Susan Minton, Hyo S. Han, Roohi Ismail‐Khan, Anthony Neuger, Fatema Khambati, David Noyes, Richard M. Lush, Alberto Chiappori, John D. Roberts,
Oncotarget

Abstract

Indoximod was safe at doses up to 2000 mg orally twice/day. Best response was stable disease >6 months in 5 patients. Induction of hypophysitis, increased tumor antigen autoantibodies and CRP levels were observed.

References

YearCitations

Page 1